Mohammad Shadid

Company: Korro Bio

Job title: VP

Seminars:

Streamlining Translation & De-risking RNAi Therapeutic Development with Optimal Selection of Preclinical Models & Appropriate Assays to Ensure Tolerable, Potent Therapies 12:01 pm

There are many promising RNAi therapeutic candidates at both the preclinical and clinical phase of development, but few drugs have yet been approved. To maximize clinical success, the right preclinical models should be used, mimicking the genotype of human patients. Assays to determine toxicity and efficacy must be precise, and dosing should be considered. Therefore,…Read more

day: Pre-Conference Workshop Day